Skip to main content

Table 3 PubMed and PMC searches for OI-MET-TF genes and cancer, BC, PC, and MET

From: A bioinformatics approach reveals novel interactions of the OVOL transcription factors in the regulation of epithelial – mesenchymal cell reprogramming and cancer progression

For 52 OI-MET-TF genes, number found in:

PubMed queries for

% PubMed

p-value

PMC queries for

% PMC

p-value

(“cancer”[ Text Word] +  OR + “ neoplasms ”[Text Word])

45

86.5%

< 0.01

48

92.3%

< 0.01

(“breast cancer”[ Text Word] +  OR + “ breast neoplasms”[ Text Word])

47

90.4%

< 0.01

49

94.2%

< 0.01

(“prostate cancer”[ Text Word] +  OR + “ prostate neoplasms”[ Text Word])

36

69.2%

< 0.01

48

92.3%

< 0.01

(“epithelial- mesenchymal transition ”[MeSH Terms])

21

40.4%

< 0.0001

38

73.1%

< 0.0001

For All 36, 973 HGNC Genes, Number found in:

PubMed queries for

  

PMC queries for

% PMC

 

(“epithelial- mesenchymal transition”[ MeSH Terms])

995

2.7%

 

1669

4.5%

 
  1. As with the OI-MET gene set “cancer”, “breast cancer”, and “prostate cancer” text word searches show that a high proportion of OI-MET-TF genes are associated with these concepts in the literature. For all six tests the empirical p-value is < 0.01. “Epithelial-mesenchymal transition” MeSH term searches show an even more significant enrichment of this annotation in the OI-MET set, relative to all genes: 40.4% ÷ 2.7% = 15.2 Fold Enrichment for PubMed; 73.1% ÷ 4.5% = 16.4 Fold Enrichment for PMC; both with p-value < 0.0001.